Loading Events

« All Events

Virtual Event
  • This event has passed.

From Mutation to Innovation: Tackling BTK Inhibitor Resistance | Justin Taylor, MD

October 9 @ 8:00 am - 9:00 am
Virtual Event

Justin Taylor, MD
Pap Corps Champions for Cancer Research Endowed Professor in Leukemia
Division of Hematology, Department of Medicine/Sylvester Comprehensive Cancer Center

Justin Taylor, M.D. is an Associate Professor in the Division of Hematology at the University of Miami Miller School of Medicine. He completed his residency at Brigham and Women’s Hospital, a fellowship at Memorial Sloan Kettering Cancer Center, and postdoctoral training with Omar Abdel-Wahab, M.D.

Dr. Taylor’s research focuses on recurrent genetic mutations in hematologic malignancies and the development of targeted therapies. His laboratory employs molecular biology, single-cell genomics, and animal models to uncover mechanisms of disease and identify novel therapeutic strategies. His work aims to translate laboratory discoveries into clinical applications to improve outcomes for patients with blood cancers.

He has received multiple research grants and has been recognized with Young Investigator Awards from the American Society of Clinical Oncology (ASCO), the Hairy Cell Leukemia Foundation, and the Evans MDS Foundation. In addition to his research, Dr. Taylor provides clinical care for patients with hematologic malignancies, integrating cutting-edge scientific insights into personalized treatment plans.

JOIN HERE!

Dr. Taylor’s objectives:

Describe the mechanisms underlying resistance to covalent and non-covalent BTK inhibitors in B-cell malignancies, including the clinical significance of both kinase-active and kinase-dead BTK mutations.

Evaluate emerging therapeutic strategies designed to overcome BTK inhibitor resistance, including targeted protein degradation and other next-generation approaches currently in preclinical and clinical development.

Integrate genomic profiling and resistance mutation analysis into the management of patients with CLL and other B-cell malignancies to inform therapeutic decision-making and clinical trial selection.

Faculty Disclosure

Dr. Taylor has indicated he has the following relevant financial relationships with ineligible companies:

Financial Relationship        Commercial Interest/organization

Consulting Fee                      AstraZeneca, CARIS Life Sciences

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.